BARBARA ANN KARMANOS CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT01416961
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT01308905
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01270880
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Medicine nd Denistry of New Jersey, Piscataway, New Jersey, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT01251952
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT01246206
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01205646
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT01147016
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01116232
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT01051570
- Locations
- 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Northshore University Health System, Evanston, Illinois, United States
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT01022138
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States